Aspira Women’s Health holders back 2026 proposals

Aspira Women’s Health Inc. reported the results of its 2026 annual stockholder meeting.

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Aspira Women’s Health Inc. reported the results of its 2026 annual stockholder meeting. Of 43,500,411 common shares entitled to vote as of the record date, 27,144,522 shares were represented, a quorum of 62.40%.

Stockholders elected all six director nominees for one‑year terms and approved, on an advisory basis, the compensation of the company’s named executive officers. They also approved an amendment to the 2019 Stock Incentive Plan to add 5,000,000 shares, bringing the total shares authorized under the plan to 9,532,818.

In addition, stockholders ratified the selection of BDO USA, P.C. as the independent registered public accounting firm for the year ending December 31, 2026.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Key Figures

Shares entitled to vote: 43,500,411 shares Shares represented at meeting: 27,144,522 shares Quorum percentage: 62.40% +3 more

6 metrics

Shares entitled to vote 43,500,411 shares Common stock issued, outstanding and entitled to vote on record date

Shares represented at meeting 27,144,522 shares Shares present in person or by proxy (62.40% quorum)

Quorum percentage 62.40% Portion of entitled shares present at 2026 annual meeting

Plan share increase 5,000,000 shares Additional shares authorized under 2019 Stock Incentive Plan

Total plan authorization 9,532,818 shares Total shares authorized under 2019 Stock Incentive Plan after amendment

Auditor ratification for votes 22,810,174 votes Votes cast for ratifying BDO USA, P.C. for year ending Dec. 31, 2026

Key Terms

broker non-votes, advisory basis, 2019 Stock Incentive Plan, independent registered public accounting firm

4 terms

broker non-votes financial

"ABSTENTIONS | | | BROKER NON-VOTES |"

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

advisory basis financial

"stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers"

2019 Stock Incentive Plan financial

"approved an amendment to the Company’s 2019 Stock Incentive Plan (the “2019 Plan”)"

independent registered public accounting firm financial

"ratified the selection of BDO USA, P.C. as the Company’s independent registered public accounting firm"

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Aspira Women’s Health (AWHL) stockholders vote on at the 2026 annual meeting?

Stockholders voted on electing six directors, approving executive compensation on an advisory basis, amending the 2019 Stock Incentive Plan, and ratifying BDO USA, P.C. as the independent registered public accounting firm for 2026.

How many Aspira Women’s Health (AWHL) shares were eligible and represented at the meeting?

A total of 43,500,411 common shares were issued, outstanding, and entitled to vote, with 27,144,522 shares present in person or by proxy, representing 62.40% of eligible shares and establishing a valid quorum.

Was the Aspira Women’s Health (AWHL) 2019 Stock Incentive Plan amendment approved?

Yes, stockholders approved increasing the shares authorized under the 2019 Stock Incentive Plan by 5,000,000, so that a total of 9,532,818 shares of common stock are authorized to be granted under the plan going forward.

Did Aspira Women’s Health (AWHL) stockholders approve executive compensation?

Yes, in a non-binding advisory vote, stockholders approved the compensation of the company’s named executive officers as described in the April 20, 2026 definitive proxy statement filed with the Securities and Exchange Commission.

Which audit firm did Aspira Women’s Health (AWHL) stockholders ratify for 2026?

Stockholders ratified the selection of BDO USA, P.C. as Aspira Women’s Health Inc.’s independent registered public accounting firm for the year ending December 31, 2026, confirming the firm’s role in auditing that fiscal year’s financial statements.

Were all Aspira Women’s Health (AWHL) director nominees elected?

Yes, all six director nominees, including Ellen Beausang and Jane Pine Wood, were elected to one-year terms expiring at the next annual meeting, each receiving more votes cast for than against their election.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/17/2026 - 04:28 PM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): June 17, 2026

ASPIRA WOMEN’S HEALTH INC.

(Exact name of registrant as specified in its charter)


Delaware		001-34810		33-0595156
(State or other jurisdiction of		(Commission		(IRS Employer
incorporation or organization)		File Number)		Identification No.)

12117 Bee Caves Road, Building III, Suite 100

Austin, TX 78738

(Address of principal executive office) (Zip Code)

(512) 519-0400

(Registrants’ telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001	AWHL	OTC QX Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 17, 2026, Aspira Women’s Health Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). As of the close of business on the record date for the Annual Meeting, there were 43,500,411 shares of the Company’s common stock, par value $0.001 per share, issued and outstanding and entitled to vote. There were 27,144,522 shares present in person or by proxy at the Annual Meeting, or 62.40%, constituting a quorum. The final voting results were as follows:

Proposal 1: Election of Directors

The Company’s stockholders elected each of the Company’s six nominees for director for a one-year term expiring at the Company’s 2026 annual meeting of stockholders and until their successors are elected and qualified, as set forth below:

NOMINEE	FOR		AGAINST		ABSTENTIONS		BROKER NON-VOTES
Ellen Beausang		5,989,004		327,224		34,689		16,569,699
Jeffrey Cohen, M.D.		5,990,548		325,667		34,702		16,569,699
John Fraser		6,278,119		38,109		34,689		16,569,699
Cynthia Hundorfean		5,991,040		325,188		34,689		16,569,699
Winfred Parnell, M.D.		5,989,187		327,040		34,690		16,569,699
Jane Pine Wood		5,983,931		332,046		34,940		16,569,699

Proposal 2: Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers

The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 20, 2026, as set forth below:

FOR				AGAINST				ABSTENTIONS				BROKER NON-VOTES
	5,568,783				505,829				276,305				16,569,699

Proposal 3: Approval of an Amendment to the Aspira Women’s Health Inc. 2019 Stock Incentive Plan

The Company’s stockholders approved an amendment to the Company’s 2019 Stock Incentive Plan (the “2019 Plan”) to increase the number of shares of common stock authorized to be granted under the 2019 Plan by 5,000,000 shares so that a total of 9,532,818 shares of common stock are authorized to be granted under the 2019 Plan, as set forth below:

FOR				AGAINST				ABSTENTIONS				BROKER NON-VOTES
	5,654,497				624,233				72,187				16,569,699

Proposal 4: Ratification of the Selection of the Company’s Independent Registered Public Accounting Firm

The Company’s stockholders ratified the selection of BDO USA, P.C. as the Company’s independent registered public accounting firm for the year ending December 31, 2026, as set forth below:


FOR		AGAINST		ABSTENTIONS		BROKER NON-VOTES
	22,810,174		15,244		95,198		0

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: June 17, 2026


	ASPIRA WOMEN’S HEALTH INC.

	By:	/s/ John Strahley
	Name:	John Strahley
	Title:	Chief Financial Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents